Ignacio J. Ansotegui M.D., Ph.D.Head of Department of Allergy and Immunology at Hospital Quironsalud Bizkaia, Bilbao, Spain
Executive Medical Director of the World Allergy Organization (WAO)
Counselor of the World Allergy Organization (WAO)
Treasurer of Global Association of Asthma (INTERASMA)
Member of the Board of Directors of the Latin-American Society of Allergy, Asthma and Immunology (SLAAI)
After finishing his medical studies at the University of Basque Country in Bilbao, Ignacio J. Ansotegui moved to the Department of Immunology and Department of Clinical Immunology at the Karolinska Institute and Karolinska Hospital of Stockholm, respectively. He completed his Spanish PhD studies in Sweden, specializing in Immunology. Later, at the University of Rome "La Sapienza", he got his second specialty in Allergology and Clinical Immunology. He is also specialist in Occupational Medicine
CURRENT AND PREVIOUS POSITION
Dr. Ansotegui is Head of Department of Allergy and Immunology at Hospital Quironsalud Bizkaia in Bilbao, Spain.
Actually he serves as Executive Medical Director and Counselor of the World Allergy Organization (WAO), Treasurer of Global Asthma Association (INTERASMA) and Member of the Board of Directors of the Latin-American Society of Allergy, Asthma and Immunology (SLAAI).
After five years in Sweden and six years in Italy, Ignacio J. Ansotegui returned to Spain in 1996 and created the Immunoallergy Laboratory at the Santiago Apostol Hospital in Vitoria-Gasteiz. Later, between 2007 and 2010, he was appointed as Consultant Allergist and Clinical Immunologist at Royal Hospitals as well as Honorary Senior Lecturer at Queen's University of Belfast, UK.
Dr. Ansotegui has chaired the Research Committee of the Latin-American Society of Allergy, Asthma and Immunology (SLAAI). Previously he served as Vice-chair (2009-2010) and Chair (2011-2012) of Iberian Chapter and member of the Board of Directors of SLAAI (2013-2014). Dr Ansotegui was Secretary General of INTERASMA from 2003 to 2006 and he also was Member at Large (2001 to 2003), 2nd Vice President (2003 –2005), Historian (2005 to 2007) and Chair of Ethics Committee (2007-2010) of the European Academy of Allergy and Clinical Immunology (EAACI). Between 2008 and 2017 he has also been secretary of the European CME Accreditation Committee. In 2008, he was the President of the European Congress of Allergy and Clinical Immunology that was held in Barcelona.
In the World Allergy Organization, Dr. Ansotegui served for four years as member at large of the Board of Directors, two years as Secretary General, two years as President Elect of the Organization and has been President of the Organization 2018-2019.
In 2007, he received the Distinguished Clinical Services Award from the Argentinean Association of Allergy and Clinical Immunology and was honored with the International Distinguished Fellow Award from the American College of Allergy, Asthma and Immunology. In 2014, he has been awarded as Honorary Member of the Italian Society of Allergology, Asthma and Clinical Immunology, and one year later, Honorary Member of the Georgian Association of Allergology and Clinical Immunology. Recently he has also been awarded as Honorary Member of the Lebanese Society of Allergy and Immunology and Honorary Member of the Argentinean Association of Allergology and Clinical Immunology.
MAIN LECTURES AND PUBLICATIONS
Ignacio J. Ansotegui has published over 170 peer reviewed articles in respected journals including Science, Journal Experimental Medicine, Biochemical Journal, Journal of Allergy and Clinical Immunology, Allergy, Journal of Investigational and Clinical Allergy, Clinical Experimental Allergy, Cellular Immunology, Scandinavian Journal of Immunology, Parasitology Today, Hybridoma, European Journal of Epidemiology, Journal American Academy of Dermatology, International Archives of Allergy and Immunology, Contact Dermatitis, European Annals of Allergy and Clinical Immunology, Anticancer Research, WAO Journal, etc.
Dr. Ansotegui has been involved as editorial board member of several journals of the specialty: Allergy, J Investigational Allergy and Clinical Immunology, International Archives of Allergy and Immunology, Annals of Respiratory Medicine, International Trends in Immunity, Asthma Research and Practice, Alergología e Inmunología Clínica and Clinical and Molecular Allergy
Prof. G. Walter Canonica
Allergist and Pulmonologist
Giorgio Walter is Professor of Respiratory Medicine at Humanitas University & Director Personalized Medicine Asthma & Allergy Center at Humanitas Research Hospital-Milano Italy Professor Canonica first specialised in pulmonary diseases after receiving his medical degree from the University of Genoa, Italy. He then specialised in allergy and clinical immunology at Florence University, Italy. He subsequently conducted clinical immunology and allergology research at several European Universities and Institutes, in addition to two years at the Medical University of South Carolina, USA. Since returning to the University of Genoa in 1995, Professor Canonica has held a number of academic positions, including Director of the Speciality School of Allergy and Clinical Immunology, Director of the Specialty School of Pulmonary Diseases and Chairman of the Department of Medical Specialties (University Hospital San Martino Genoa, Italy). He is a Board Member of ARIA-Allergic Rhinitis and its Impact on Asthma and helped to develop their guidelines.
He has been President of WAO-World Allergy Organization, Interasma-Global Asthma Association, currently VicePresident of REG-Respiratory Effectiveness Group.
He is Steering Committee Member of SANI-Severe Asthma Network Italy.
Dr. Alan KaplanMD CCFP(EM) FCFP
Family Physician practicing in York Region, Ontario, Canada.
Past- Chairperson of the Respiratory Section of the College of Family Physicians of Canada
Senate member of the International Primary Care Respiratory Group
President of the IPCRG 5th biennual world scientific meeting, “Making Every Breath Count” Toronto June 2-5, 2010
Chair of the Council of Organizing Members of the Canadian Network for Respiratory Care.
Member of Past Canadian Consensus Guidelines for H pylori, Asthma, COPD and Sinusitis
Representative of the College of Family Physicians of Canada to the SARS clinical working group.
Member of Chronic Respiratory Disease Surveillance Advisory Committee (Public Health Agency of Canada)
Member of the Health Canada Section on Allergy and Respiratory Therapies
Member of the Canadian Metropolitan Tuberculosis Subcommittee
Co-Chair, Health Quality Ontario COPD Community Management standards committee
Board member, Thrombosis Canada
Vice President, Respiratory Effectiveness Group
International editor for Nature’s Primary Care Respiratory Journal
International editor for the Italian Journal of Primary Care
Non-respiratory medical interests:
Community Pain consultant
Palliative Care community physician
Hospitalist, Brampton Civic Hospital
Married with four children and four dogs
Ardent baseball player
Dr. Federico Lavorini
Dr Marc Miravitlles
Marc Miravitlles is a Pulmonologist at the Hospital Universitari Vall d’Hebron in Barcelona, Spain. He obtained his MD at the Universitat de Barcelona, Barcelona, Spain and then specialised in Respiratory Medicine at Hospital Vall d'Hebron. His primary research interests include chronic obstructive pulmonary disease (COPD), alpha-1-antitrypsin deficiency (AAT), lung defence mechanisms and respiratory infections. He serves on various medical committees and is a member of numerous professional societies, including the Spanish Society of Pneumology and Thoracic Surgery (SEPAR), where he served as Secretary from 1999 until 2003 and responsible for International Relationships from 2006 until 2012. Dr Miravitlles was Chair of the Respiratory Infections Group of the European Respiratory Society (ERS) from 2008 to 2011 and was the Guidelines Director of the ERS from 2015 to 2018. He has acted as a consultant for the development of different international guidelines of COPD, including the American Thoracic Society (ATS)/ERS task force on outcomes in COPD, the ERS/ATS guidelines on exacerbations of COPD and the ERS statement on management of alpha-1 antitrypsin deficiency. He is also a consultant of the Spanish Ministry of Health for the development of the National Strategy Against COPD (2009 to present). He is the coordinator of the Spanish National Guidelines for COPD (GesEPOC from 2012).
Nicolas Roche is Professor of Respiratory Medicine at Cochin Hospital, University of Paris Descartes, France. His major areas of interest are COPD and asthma with particular focus on inhaled therapy, disease phenotypes, assessment tools, treatment strategies and real-life research.
Professor Roche is a member of the GOLD science committee, President of Société de Pneumologie de Langue Française, co-chair of the 2018 ERS Congress and member of the American Thoracic Society. He is guidelines director of the ERS and member of the ERS Clinical Research Collaboration (CRC) working group and ERS Science Council, vice-president of the Respiratory Effectiveness Group and member of the Asthma Drug Management Improvement Team. He coordinates French guidelines on COPD and is a consultant for French institutions for the development of national projects on COPD.
Professor Roche has authored more than 250 research articles in international peer-reviewed journals and edited or co-edited several books on COPD. He is Associate Editor of the European Respiratory Review and the Clinical Respiratory Journal.
Joan B SorianoAssociate Professor of Medicine, Universidad Autónoma de Madrid, and Senior Investigator at the Instituto de Investigación Hospital Universitario de la Princesa-IISP, Madrid, Spain
Bariton at the Opera Choir of Teatre Principal de Palma, Palma de Mallorca, Spain
He serves in the GesEPOC COPD guidelines, has been Methodologic and Scientific Consultant of SEPAR and Director of its Foreign Affairs, participates in several committees of the Ministry of Health of Spain, and collaborates extensively with both the ERS and CHEST. He spends most of his time dedicated to research on COPD and other respiratory conditions, aging and tobacco, the design of new clinical trials and translational Medicine. Since 2007 he is Associate Editor of the European Respiratory Journal and since 2012 of the Lancet Respiratory Medicine, and peer reviews extensively for others. He has 300+ publications in PubMed in the fields of clinical epidemiology and treatment of respiratory diseases, and a Hirsh index of 80+. In May 2011 he received the Josep Trueta Award for scientific and medical achievements, and in 2014 he was appointed FCCP from Chest and Foundational Fellow of the ERS (FERS).
He has authored several REG papers and participated actively in many of its past conferences. He is in the REG Board since 2019.
Prof. Johann Christian Virchow
He has published more than 260 peer reviewed papers on pulmonary diseases with a focus on asthma and COPD.
Prof. David Halpin
He is also Honorary Professor of Respiratory Medicine at the Observational and Pragmatic Research Institute (OPRI) in Singapore. He is a member of the Board of Directors of the Global Initiative on Obstructive Lung Diseases (GOLD) and of the GOLD Science Committee. He was the Chairman and Clinical Expert for the COPD Guideline Development Group of the National Institute of Clinical Excellence (NICE) in the UK.
He studied at Oxford University (first class honours) & St Thomas Hospital Medical School, qualifying in 1986. He was awarded an MRC scholarship to undertake a D.Phil. in the Department of Human Anatomy at Oxford University, between his pre-clinical and clinical training. He trained in respiratory medicine at the Brompton Hospital in London.
He is a Fellow of Royal College Physicians, and a Member of the BTS, ERS & ATS.
He has served on various BTS committees.
In 2018 he was elected as a Fellow of ERS in recognition of lifetime excellence and contributions to research, education and clinical leadership in respiratory medicine.
His research is focussed on clinical aspects of COPD and asthma. He has published extensively and frequently gives presentations on COPD and asthma at lectures and meetings around the world.
He was an Associate Editor of Thorax and is on the editorial board of several journals and is a peer reviewer for many others.
Prof. Alberto Papi
He trained in Respiratory Medicine at the University of Parma, before spending 4 years in the UK as a Clinical Research Fellow at the University of Southampton, where he is an Honorary Clinical Lecturer.
He has coordinated several pivotal studies in asthma and COPD, and has authored more than 350 articles in peer-reviewed journals.
Prof. David Price
Prof. Job van Boven
He obtained his PharmD and PhD at the University of Groningen (The Netherlands), where his thesis focused on the cost-effectiveness of adherence enhancing interventions in patients with COPD. After his PhD research, he completed fellowships at the University of Colorado (USA), Monash University (Australia) and the Hospital Universitario Son Espases (Spain).
He is (co)author of >100 scientific publications, supervisor of 9 PhD students and received several research prices & grants (totalling>€6 million). Having interest and wide experience in both medication adherence and health economic methods, his mission is to find novel, cost-effective ways to make better use of our respiratory medications in order to maximize both patients’ and societal benefits. Amongst others, his research aims to provide evidence for optimal implementation of drug-device technologies (digital inhalers, electronic pill bottles and smart spacers) in daily clinical practice.
Professor Sinthia Bosnic-Anticevich
Professor Sinthia Bosnic-Anticevich is an internationally recognised leader in in the field of respiratory medicines. She is the founder and Team Leader of the Quality Use of Respiratory Medicines Group, located at the Woolcock Institute, University of Sydney and Sydney Local Health District. The group focuses on generating new knowledge about the use of respiratory medicines from the patient, health care provider and societal perspective with output of over 120 research publications in the area. The research of Professor Bosnic-Anticevich and her group has changed the landscape of inhaler technique research; impacting on national and international treatment guidelines. Her research has been critical to our understanding of the role of respiratory medication use in the precision medicine approach to respiratory disease management. Professor Bosnic-Anticevich works across the continuum of the health care settings, with a multidimensional and inter-professional approach to better understand and improving health outcomes for patients using respiratory medicines.
She is on the executive of ARIA (Allergic Rhinitis in Asthma) and chair of Pharmacy ARIA, which is the leading global initiative for the management of Allergic Rhinitis in pharmacy. Sinthia Bosnic-Anticevich’s role as Chair of this group is to lead the development of the Pharmacy ARIA guidelines and to work with international experts in the field to develop guidelines for pharmacy that can integrate the practice of pharmacy across the health disciplines. The latest Pharmacy ARIA guidelines are currently under review.
Professor Bosnic-Anticevich is Vice President of the Respiratory Effectiveness Group (REG), an investigator-led, not-for-profit research initiative that has been set up in recognition of the potential value of real-life research and the need to harness real-life evidence to inform meaningful practice guidelines, drug licensing and prescribing decisions. In this capacity she provides international leadership in setting research standards and excellence in real-life research and in evaluating mechanisms for integrating real-life research into clinical guidelines and practice. Currently there are over 300 researchers within the REG network.
Michael E Wechsler, MD, MMScProfessor of Medicine, National Jewish Health
Director, NJH Cohen Family Asthma Institute
Associate Vice President for Innovation and Industry Relations
in the Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA
Michael E. Wechsler is Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at NJH in Denver, Director of the National Jewish Health (NJH)/Cohen Family Asthma Institute and Associate Vice President for Innovation and Industry Relations at NJH. In addition to clinical work in pulmonary & critical care medicine, Professor Wechsler’s research focuses on clinical and translational asthma with emphasis on clinical trials in asthma, novel asthma therapies, bronchial thermoplasty, asthma pharmacogenomics, and management of eosinophilic granulomatosis with polyangiitis (i.e. Churg-Strauss Syndrome, CSS). He has led studies focusing on novel biologic agents for asthma and related diseases, including benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. He has published more than 290 manuscripts relating to asthma, EGPA and eosinophilic lung diseases. He was a member of the Steering Committee and site Principal Investigator of the NIH-sponsored Asthma Clinical Research Network (ACRN, now called AsthmaNet), a multicentre asthma clinical trials consortium, and currently serves as the PI of the Denver site of the Precision Intervention in Severe/Exacerbating Asthma (PRECISE) network. A member of the American Society of Clinical Investigation and the Association of American Physicians, he has participated in many different task forces related to the study of eosinophilic lung diseases that were sponsored by the NIH, the FDA, the European Respiratory Society and the International Eosinophil Society. He is currently Associate Editor of the journal Chest and has served as Associate Editor of the journal Allergy and on the editorial board of the European Journal of Clinical Investigation.
Dr. Wechsler received AB and MMSc degrees from Harvard University in Boston and an MD degree from McGill University in Montreal. He completed medical training at Beth Israel Hospital in Boston, and as part of the Harvard Combined Pulmonary and Critical Care Fellowship Training Program.